-

Shareholder Alert: Robbins LLP is Investigating QuantumScape Corporation (QS) for Shareholders

SAN DIEGO & SAN JOSE, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating QuantumScape Corporation (NYSE: QS) to determine whether certain of the Company's officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. QuantumScape develops battery technology for electric vehicles and other applications.

If you suffered a loss due to QuantumScape Corporation's misconduct, click here.

QuantumScape Corporation (QS) Misled Shareholders by Overstating the Viability, Power and Life of its Solid-State Battery

According to a complaint filed against the complaint, on November 27, 2020, QuantumScape went public via a business combination with Kensington Capital Acquisition Corp. A joint press release issued by QuantumScape and Kensington, characterized QuantumScape as "a leader in the development of next generation solid-state lithium-metal batteries for use in electric vehicles." Throughout the relevant period, QuantumScape touted the success of its battery technology.

On January 4, 2021, Seeking Alpha published an article pointing to several risks with QuantumScape's solid-state batteries that make it "completely unacceptable for real world field electric vehicles." The article stated that the battery's power "will only last for 260 cycles or about 75,000 miles of aggressive driving." As solid-state batteries are temperature sensitive, "the power and cycle tests at 30 and 45 degrees above would have been significantly worse if run even a few degrees lower." The article further detailed significant challenges QuantumScape faces. On this new, QuantumScape's stock plummeted $34.49, or over 40%, to close at $49.96 per share on January 4, 2021. The stock is currently trading just over $27.00.

QuantumScape Corporation (QS) Shareholders have Legal Options. If you would like more information regarding your rights, please contact Lauren Levi at (800) 350-6003 or llevi@robbinsllp.com, or via our Shareholder Information Form.

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against QuantumScape settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom